LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN

13841 reported adverse events

Drug classes: Radioligand Therapeutic Agent [EPC]

These side effects are most commonly reported by patients taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN:

# Side effect Count
0 GENERAL PHYSICAL HEALTH DETERIORATION 6684
1 ILL-DEFINED DISORDER 3641
2 DEATH 1321
3 DISEASE PROGRESSION 360
4 MALIGNANT NEOPLASM PROGRESSION 343
5 PROSTATIC SPECIFIC ANTIGEN INCREASED 287
6 LABORATORY TEST ABNORMAL 266
7 FATIGUE 238
8 ANAEMIA 204
9 PLATELET COUNT DECREASED 168
See all common reactions for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN

LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HORMONE-DEPENDENT PROSTATE CANCER 10 0.1429
1 HORMONE-REFRACTORY PROSTATE CANCER 167 0.1406
2 ILL-DEFINED DISORDER 3641 0.0599
3 GENERAL PHYSICAL HEALTH DETERIORATION 6684 0.0577
4 METASTASES TO NERVOUS SYSTEM 9 0.0489
5 PROSTATIC SPECIFIC ANTIGEN DECREASED 15 0.0397
6 PROSTATE CANCER METASTATIC 84 0.0251
7 PROSTATIC SPECIFIC ANTIGEN ABNORMAL 24 0.0231
8 PROSTATIC SPECIFIC ANTIGEN INCREASED 287 0.0208
9 BLOOD CHROMOGRANIN A INCREASED 9 0.0196
See all enriched reactions for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN